2024
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
Varga C, Robinson M, Gupta V, Hofmeister C, Nooka A, Kaufman J, Dhodapkar M, Lonial S, Borden S, Ferreri C, Paul B, Atrash S, Bhutani M, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes. Blood 2024, 144: 4702-4702. DOI: 10.1182/blood-2024-204388.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaCD34+ cells/kgStem cell collectionStem cell yieldLevine Cancer InstituteNewly diagnosed multiple myeloma patientsStem cell mobilizationCD34+ cellsInduction therapyCell collectionG-CSFNo significant differenceDose of G-CSFISS stage III diseaseTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCancer InstituteHigh-risk cytogeneticsMedian patient ageMRD-negative statusStage III diseaseStem cell harvestWinship Cancer InstituteSignificant difference
2023
Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristics